Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists Journal Article
| Authors: | Rugo, H. S.; Bardia, A.; Gradishar, W. J.; Hamilton, E. P.; Hurvitz, S. A.; Jhaveri, K.; Mahtani, R.; Tolaney, S. M. |
| Article Title: | Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists |
| Abstract: | Hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2-mBC) is incurable, but recent progress has been made in developing new treatment options and the treatment landscape is rapidly shifting. There are published recommendations for treatment choices and sequencing to help guide oncologists in treating HR+/HER2-mBC, but little evidence has been published regarding real-world practice patterns. The REal-world TReatment patterns And Considerations of Toxicity in HR+/HER2-mBC (RETRACT) survey was designed to evaluate real-world practice patterns in the testing and management of this disease by US oncologists. The survey questions were answered via an online platform and the data were anonymized before analysis. A total of 150 oncologists practicing at academic and community centers completed the survey. The results showed this sample of oncologists largely followed recommended best practices for testing biomarkers, selecting treatments, and managing adverse events. However, several items did show substantial minorities of oncologists not in alignment with recommendations in areas including the definition and treatment of visceral crisis, ideal treatment for patients with endocrine resistance, the routine use of next-generation sequencing for biomarker testing, and the use of prophylactic measures for treatment-related adverse events in patients receiving alpelisib. © 2025 |
| Keywords: | adult; fatigue; diarrhea; side effect; united states; adjuvant therapy; antineoplastic agent; clinical practice; medical decision making; biological marker; nausea; peripheral neuropathy; olanzapine; epidermal growth factor receptor 2; aromatase inhibitor; exercise; patient monitoring; exemestane; hyperglycemia; pneumonia; rash; tumor suppressor gene; cancer center; sexual dysfunction; nonsteroid antiinflammatory agent; data analysis; glucose blood level; consensus development; interstitial lung disease; acupuncture; hot flush; corticosteroid; hormone receptor; metastatic breast cancer; cyclin dependent kinase inhibitor; university hospital; everolimus; musculoskeletal disease; normal human; medical expert; human epidermal growth factor receptor 2; fulvestrant; antihistaminic agent; aprepitant; gabapentin; cryotherapy; duloxetine; drug choice; online system; oncologist; germline mutation; protocol compliance; practice guidelines; side effects; high throughput sequencing; treatment patterns; hormone derivative; phosphatidylinositol 4,5 bisphosphate 3 kinase; human; article; best practice; hormone receptor positive breast cancer; alpelisib; ribociclib; body weight gain; human epidermal growth factor receptor 2 negative breast cancer; trastuzumab deruxtecan; anonymised data; capivasertib; biomarker testing; elacestrant |
| Journal Title: | Breast |
| Volume: | 82 |
| ISSN: | 0960-9776 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2025-08-01 |
| Start Page: | 104485 |
| Language: | English |
| DOI: | 10.1016/j.breast.2025.104485 |
| PROVIDER: | scopus |
| PUBMED: | 40344957 |
| PMCID: | PMC12138406 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
